Consumers and Providers Face Biosimilar Knowledge Hurdles

AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars

March 20th 2024

By Skylar Jeremias

Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.

Biosimilar Growth Hormone Reveals Efficacy, Safety in Real-World Pediatric PATRO Study

March 19th 2024

By Cameron Santoro

A large-scale study found that Omnitrope, a biosimilar growth hormone, is effective and well-tolerated in treating various growth disorders in children.

Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake

March 18th 2024

By Skylar Jeremias

Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.

BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere

March 18th 2024

By Sarfaraz K. Niazi, PhD

Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.

Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars

March 17th 2024

By Skylar Jeremias

On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.

Adalimumab Expenditures in Countries With and Without Available Biosimilars

March 16th 2024

By Deana Ferreri, PhD

A recent study used difference-in-difference analysis to assess adalimumab sales volumes and expenditures in 6 countries with and 8 countries without available biosimilar adalimumab products.

The Top 5 Biosimilar Articles for the Week of March 11

March 15th 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of March 11, 2024.

Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth

March 14th 2024

In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.

Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics

March 14th 2024

By Skylar Jeremias

Posters from Association of Cancer Care Centers 50th Annual Meeting and Cancer Center Business Summit (AMCCBS) and the American Academy of Dermatology (AAD) highlight the benefits of incorporating biosimilars into electronic medical records and the biggest barriers for home injection of biologics.

Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio

March 13th 2024

By Skylar Jeremias

A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.